SAN DIEGO—(BUSINESS WIRE)—Aug. 5, 2004—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativescience to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report second quarter 2004 financial results on Wednesday,August 11, 2004, after the U.S. financial markets close.
ACADIA will host a conference call and webcast on Wednesday,August 11, 2004 at 4:30 p.m. EDT to discuss financial results for thesecond quarter ended June 30, 2004. Uli Hacksell, Ph.D., ACADIA'sChief Executive Officer, will also provide an update on the Company'sprogress.
The conference call may be accessed by dialing 800-901- 5231 forparticipants from the United States or Canada and 617-786-2961 forinternational callers (reference participant passcode 69887488). Theconference call will also be webcast live on ACADIA's website athttp://www.acadia-pharm.com, under the investor relations section, andwill be archived there until August 25, 2004
This call is being webcast by Thomson/CCBN and can be accessed atAcadia's Web site at www.acadia-pharm.com.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizinginnovative science to fuel drug discovery and clinical development ofnovel treatments for central nervous system disorders. ACADIAcurrently has five drug programs in clinical and preclinicaldevelopment directed at large unmet medical needs and major commercialmarkets, including Parkinson's disease, schizophrenia, chronic pain,and glaucoma. Using its proprietary drug discovery platform, ACADIAhas discovered all of the drug candidates in its product pipeline.ACADIA's corporate headquarters and biological research facilities arelocated in San Diego, California and its chemistry research facilitiesare located in Copenhagen, Denmark.
CONTACT: ACADIA Pharmaceuticals, Inc.
Thomas H. Aasen, 858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.